<unk> , sold under the brand name Caplyta, is a medication used for the treatment of schizophrenia and bipolar depression. It is a butyrophenone atypical antipsychotic developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb. The most common side effects include sleepiness and dry mouth.<unk>  was approved for medical use in the United States in December 2019, and became available in February 2020.
Lumateperone
Tolperisone
Buffalopox
Tesofensine
Bremazocine
Eptazocine
Cidoxepin
Clorotepine